- Conditions
- HIV Infections
- Interventions
- gp160 Vaccine (Immuno-AG), Hepatitis B Vaccine (Recombinant)
- Biological
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1998
- U.S. locations
- 2
- States / cities
- Baltimore, Maryland • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 1, 2021 · Synced May 22, 2026, 3:41 AM EDT